Список литературы

1. Hirota, S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577 - 580 (1998).

2. Miettinen M., Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol. J. Pathol. - 2003. - N 54, - Р. 3 - 24.

3. П.П. Архири, Н.Ц. Цымжитова, И.С. Стилиди, И.В. Поддубная, М.П. Никулин, И.В. Цыганова, О.А. Анурова, Н.Н. Мазуренко. Клиническое и прогностическое значение мутационного статуса у больных гастроинтестинальными стромальными опухолями. Саркомы костей, мягких тканей и опухоли кожи N 1 - 2013. С. - 42 - 46.

4. Peter Arhiri, Ivan S. Stilidi, I. Poddubnaya, Maxim P. Nikulin, N. Tsymzhitova, N.N. Mazurenko. Clinical significance of mutational status in gastrointestinal stromal tumors (GIST). J Clin Oncol 30, 2012 (suppl; abstr 20501).

5. Corless, C. L., Barnett, C. M., & Heinrich, M. C. (2011). Gastrointestinal stromal tumours: Origin and molecular oncology. Nature Reviews Cancer, 11(12), 865 - 878.

6. Corless CL, Biology of gastrointestinal stromal tumors./Fletcher JA, Heinrich MC. J. Clin. Oncol. 2004. - Vol. 22, - P. 3813 - 3825.

7. Christopher L. Corless, Christine M. Barnett, Michael C. Heinrich. Gastrointestinal stromal tumours: origin and molecular oncology. Nature Reviews Cancer, 2011; doi:10.1038/nrc3143.

8. Lasota J. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)./Miettinen M.//Semin. Diagn. Pathol. 2006. - Vol. 23, - P. 91-1

9. Никулин М.П., Стилиди И.С. Гастроинтестинальные стромальные опухоли (ГИСО). Эпидемиология, диагностика, современные подходы к лечению. Современная онкология. Экстра выпуск 2007. - С. 3 - 50.

10. Joensuu Heikki. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human pathology (2008) 39, 1411 - 1419.

11. Agaimy A. Minute, Wunsch PH, Hofstaedter F. Gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am. J. Surg. Pathol. 2007. - Vol. 31, - P. 113 - 120.

12. Miettinen M., Lasota J. Gastrointestinal Stromal Tumors. Review on Morphology, Molecular Pathology, Prognosis, and Differential Diagnosis. Arch. Pathol. Lab. Med. - 2006. - N 130, - Р. 1466 - 1476.

13. Стилиди И.С., П.П. Архири, М.П. Никулин. Хирургическое лечение больных с первичными локализованными и местнораспространенными гасроинтестинальными стромальными опухолями/Вестник РОНЦ им. Н.Н. Блохина РАМН, - 2010, - 21, (1), - С. 77 - 82.

14. П.П. Архири, И.С. Стилиди, И.В. Поддубная, С.Н. Неред, М.П. Никулин, В.Ю. Бохян, О.Б. Абу-Хайдар, И.Н. Перегородиев, С.А. Меликов, Н.Ц. Цымжитова. Эффективность хирургического лечения больных с локализованными стромальными опухолями желудочно-кишечного тракта (ЖКТ). Российский онкологический журнал N 5, 2016, Том 21, С 233 - 237

15. Eisenberg BL. Judson I. Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; - N 11, - P. 465 - 475.

16. De Matteo R.P, Heinrich M.C, El-Rifai. W.M Clinical management of gastro-intestinal stromal tumors: before end after STI-571. Hum. Patho. J. - 1999. - N 30, - P. 1213 - 20.

17. De Matteo RP. Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; - Vol. 231, - P. 51 - 8.

18. Demetri G., Benjamin R., Blanke C. et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. ... - 2007; 5 (Suppl 2): S1 - S29.;

19. Piotr Rutkowski. Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience/Alessandro Gronchi, Peter Hohenberger, Sylvie Bonvalot, Patrick , Sebastian Bauer, Elena Fumagalli, Pawel Nyckowski, Buu-Phuc Nguyen, Jan Martijn Kerst, Marco Fiore, Elzbieta Bylina, Mathias Hoiczyk, Annemieke Cats, Paolo G. Casali, Axel Le Cesne, Treckmann, Eberhard Stoeckle, Johannes. H. W. de Wilt, Stefan Sleijfer, Ronald Tielen, Winette van der Graaf, Cornelis Verhoef, Frits van Coevorden//Ann Surg Oncol (2013) 20: 2937 - 2943.

20. Corless C.L., Ballman K.V., Antonescu C. et al. Relation fo tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST). Results of the intergroup phase III trial ACOSOG Z9001//J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2010. Vol. 28. N 15. Suppl. Abstract 10006.

21. Joensuu H., Eriksson M., Hatrmann J. et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2011. Vol. 29. N 18. Suppl. Abstract LBA1.

22. Blay J.Y. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. Cancer Treat. Rev. 2011. Vol. 37. N 5. P. 373 - 384.

23. Casali, PG, Jost, L, Reichardt, P, Schlemmer, M, Blay, JY, 2008. "ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment anf follow-up,"Ann Oncol., 19 Suppl. 2, pp. 35 - 38.

24. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard - versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26(4): 620 - 5.

25. Le Cesne A., Ray-Coquard I., Bui B.N. et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010. Vol. 11. N 10. P. 942 - 949.

26. Van Glabbeke M. Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analisys of 1,640 Patients. Journal of Clinical Oncology, Vol 28, N 7, March 1, 2010, p. 1247 - 1253.

27. Verweij J., Casali P.G, Zalcberg J. Progression free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, - Vol. 364, - P. 1127 - 34.

28. Antonescu C. R. Acquired Resistance to Imatinib in Gastrointestinal StromalTumor Occurs Through Secondary Gene Mutation./Besmer Peter, Tianhua Guo, Knarik Arkun, Glory Hom, Beata Koryotowski, Margaret A. Leversha, Philip D. Jeffrey, Diann Desantis, Samuel Singer, Murray F. Brennan, Robert G.Maki, Ronald P. DeMatteo//Clin Cancer Res 2005. - Vol. 1, - P. - 4182 - 4190.

29. Mudan S.S., Conlon K.C, Woodruff J.M. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selectiaon. Cancer 2000; - Vol. 88, - P. 66 - 74.

30. Raut C.P., Posner M, Desai J, Morgan J.A, George S, Zahrieh D, Fletcher C.D, Demetri G.D, Bertagnolli M.M. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=16710031%5BUID%5D). J. Clin. Oncol. 2006 May 20; - Vol. 24, - N 15, - P. 2325 - 31.

31. Rutkowski P. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate./Nowecki Z, Nyckowski P//J Surg Oncol 2006, - N 93, - P. 304 - 311.

32. И.С. Стилиди, П.П. Архири, М.П. Никулин. Хирургическое лечение больных с рецидивными и метастатическими стромальными опухолями желудочно-кишечного тракта. Вопросы онкологии 4-2011, Т 57, стр. 508 - 512

33. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329 - 38.

34. Heinrich M.C., Maki R.G., Corless C.L. et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol. 2008. Vol. 26. N 33. P. 5352 - 5359.

35. Heinrich M.C., Maki R.G., Corless C.L. et al. Sunitinib (SU) response in imatinib-resistance (IM-R) GIST correlates with KIT and PDGFRA mutation status. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2006. Vol. 24. N 18S. Suppl. Abstract. 9502.

36. Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26; 381(9863): 295 - 302.